Horizon Pharma PLC (NASDAQ:HZNP) is scheduled to release its earnings data before the market opens on Monday, November 6th. Analysts expect Horizon Pharma PLC to post earnings of $0.22 per share for the quarter.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The business had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the prior year, the business posted $0.56 EPS. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts expect Horizon Pharma PLC to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Horizon Pharma PLC (NASDAQ:HZNP) opened at $14.17 on Friday. The firm has a market cap of $2.26 billion, a P/E ratio of 8.24, a PEG ratio of 2.11 and a beta of 1.32. The company has a debt-to-equity ratio of 1.83, a current ratio of 1.61 and a quick ratio of 1.46.
ILLEGAL ACTIVITY NOTICE: “Horizon Pharma PLC (HZNP) Scheduled to Post Earnings on Monday” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/11/04/horizon-pharma-plc-hznp-scheduled-to-post-earnings-on-monday.html.
A number of analysts recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price target on shares of Horizon Pharma PLC in a research report on Sunday, October 22nd. ValuEngine upgraded Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Sunday, October 15th. Zacks Investment Research downgraded Horizon Pharma PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $16.00 target price on shares of Horizon Pharma PLC in a research report on Thursday, October 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.00.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
What are top analysts saying about Horizon Pharma PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Horizon Pharma PLC and related companies.